Chinook Therapeutics Inc. (NASDAQ:KDNY) went up by 13.58% from its latest closing price compared to the recent 1-year high of $18.41. The company’s stock price has collected 8.12% of gains in the last five trading sessions.
Is It Worth Investing in Chinook Therapeutics Inc. (NASDAQ :KDNY) Right Now?
Plus, the 36-month beta value for KDNY is at 0.02. Opinions of the stock are interesting as 8 analysts out of 8 who provided ratings for Chinook Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $35.29, which is $15.92 above the current price. KDNY currently public float of 43.89M and currently shorts hold a 5.14% ratio of that float. Today, the average trading volume of KDNY was 534.26K shares.
KDNY’s Market Performance
KDNY stocks went up by 8.12% for the week, with a monthly jump of 48.13% and a quarterly performance of 24.33%, while its annual performance rate touched 22.86%. The volatility ratio for the week stands at 9.59% while the volatility levels for the past 30 days are set at 9.10% for Chinook Therapeutics Inc. The simple moving average for the period of the last 20 days is 17.57% for KDNY stocks with a simple moving average of 31.71% for the last 200 days.
Analysts’ Opinion of KDNY
Many brokerage firms have already submitted their reports for KDNY stocks, with Wedbush repeating the rating for KDNY by listing it as a “Outperform.” The predicted price for KDNY in the upcoming period, according to Wedbush is $28 based on the research report published on January 06th of the previous year 2021.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see KDNY reach a price target of $31. The rating they have provided for KDNY stocks is “Overweight” according to the report published on December 10th, 2020.
H.C. Wainwright gave a rating of “Buy” to KDNY, setting the target price at $28 in the report published on November 16th of the previous year.
KDNY Trading at 22.88% from the 50-Day Moving Average
After a stumble in the market that brought KDNY to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 1.30% of gains for the given period.
Volatility was left at 9.10%, however, over the last 30 days, the volatility rate increased by 9.59%, as shares surge +34.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.56% upper at present.
During the last 5 trading sessions, KDNY rose by +8.12%, which changed the moving average for the period of 200-days by +38.25% in comparison to the 20-day moving average, which settled at $16.10. In addition, Chinook Therapeutics Inc. saw 14.35% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at KDNY starting from AKKARAJU SRINIVAS, who purchase 570,000 shares at the price of $14.00 back on May 27. After this action, AKKARAJU SRINIVAS now owns 5,161,888 shares of Chinook Therapeutics Inc., valued at $7,980,000 using the latest closing price.
DOBMEIER ERIC, the President, CEO of Chinook Therapeutics Inc., purchase 5,000 shares at $13.03 during a trade that took place back on May 25, which means that DOBMEIER ERIC is holding 205,880 shares at $65,148 based on the most recent closing price.
Stock Fundamentals for KDNY
Equity return is now at value -26.90, with -20.70 for asset returns.